Product/Composition:- | Dasatinib |
---|---|
Strength:- | 20 mg, 50 mg, 70 mg, 100 mg, 140 mg |
Form:- | Tablet |
Reference Brands:- | Sprycel® (EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Dasatinib is an oral tyrosine kinase inhibitor for treating CML and ALL. Available in 20 mg, 50 mg, 70 mg, 100 mg, and 140 mg tablets, it is marketed as Sprycel® in the US and EU, offering key B2B opportunities in oncology.
Dasatinib is an oral tyrosine kinase inhibitor (TKI) used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). By targeting the BCR-ABL fusion protein, Dasatinib effectively blocks the signals that drive the growth of cancer cells. Available in tablet forms of 20 mg, 50 mg, 70 mg, 100 mg, and 140 mg, it offers a flexible dosing regimen for oncologists. Sprycel® (Dasatinib) is widely available in both the US and EU, providing essential treatment options for leukemia patients. This presents significant B2B opportunities for pharmaceutical manufacturers in these markets.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications